Rottapharm Biotech
- Biotech or pharma, therapeutic R&D
Our goal is to present our asset CR6086, a prostaglandin EP4 receptor antagonist, available for partnering in immuno-oncology.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}